{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:57:14Z","timestamp":1790035034882,"version":"4.0.1"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ymgmr.2020.100604","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T20:33:57Z","timestamp":1590006837000},"page":"100604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Intravenous delivery for treatment of mucopolysaccharidosis type I: A comparison of AAV serotypes 9 and rh10"],"prefix":"10.1016","volume":"24","author":[{"given":"Lalitha R.","family":"Belur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"Podetz-Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy An","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Mesick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel M.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Vulchanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen F.","family":"Kozarsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Scott","family":"McIvor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2020.100604_bb0005","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3421","article-title":"The mucopolysaccharidoses","author":"Neufeld","year":"2001"},{"key":"10.1016\/j.ymgmr.2020.100604_bb0010","doi-asserted-by":"crossref","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","article-title":"Overview of the mucopolysaccharidoses","volume":"50","author":"Muenzer","year":"2011","journal-title":"Rheumatol"},{"key":"10.1016\/j.ymgmr.2020.100604_bb0015","first-page":"102","article-title":"Mucopolysaccharidosis type I","volume":"12","author":"Wraith","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0020","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/096368979500400409","article-title":"Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases","volume":"4","author":"Krivit","year":"1995","journal-title":"Cell Transplant."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0025","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00281-004-0166-2","article-title":"Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases","volume":"26","author":"Krivit","year":"2004","journal-title":"Springer Seminars Immunopathol."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0030","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jpeds.2007.04.054","article-title":"Hematopoietic cell therapy for metabolic disease","volume":"151","author":"Orchard","year":"2007","journal-title":"J Pediatrics"},{"key":"10.1016\/j.ymgmr.2020.100604_bb0035","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.expneurol.2003.11.005","article-title":"Hematopoietic origin of microglial and perivascular cells in brain","volume":"186","author":"Hess","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0040","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.seminhematol.2009.10.008","article-title":"Transplant outcomes in mucopolysaccharidoses","volume":"47","author":"Prasad","year":"2010","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0045","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1182\/blood.V87.11.4894.bloodjournal87114894","article-title":"Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome","volume":"87","author":"Peters","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ymgmr.2020.100604_bb0050","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ajmg.1320460222","article-title":"Long-term outcome of Hurler syndrome following bone marrow transplantation","volume":"46","author":"Whitley","year":"1993","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.ymgmr.2020.100604_bb0055","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/sj.bmt.1704105","article-title":"Outcome of 27 patients with Hurler\u2019s syndrome transplanted from either related or unrelated haematopoietic stem cell sources","volume":"31","author":"Souillet","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0060","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2004.07.003","article-title":"Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I","volume":"83","author":"Kakkis","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0065","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2165\/00003495-200767180-00005","article-title":"Treatment of lysosomal storage disorders: progress with enzyme replacement therapy","volume":"67","author":"Rohrbach","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.ymgmr.2020.100604_bb0070","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1002\/ajmg.a.32294","article-title":"Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression","volume":"146A","author":"Munoz-Rojas","year":"2008","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgmr.2020.100604_bb0075","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ymgme.2006.12.012","article-title":"Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid","volume":"91","author":"Dickson","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0080","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.2174\/138161208784705504","article-title":"Lysosomal storage diseases and the blood-brain barrier","volume":"14","author":"Begley","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0085","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1182\/blood-2010-04-278234","article-title":"Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model","volume":"116","author":"Visigalli","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymgmr.2020.100604_bb0090","doi-asserted-by":"crossref","first-page":"19958","DOI":"10.1073\/pnas.0908528106","article-title":"Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome","volume":"106","author":"Wang","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0095","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1073\/pnas.1323155111","article-title":"Platelets are efficient and protective depots for storage, distribution, and delivery of lysosomal enzyme in mice with Hurler syndrome","volume":"111","author":"Dai","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.ymgmr.2020.100604_bb0100","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1089\/hum.2016.068","article-title":"Preclinical testing of the safety and tolerability of lentiviral vector-mediated above-normal alpha-L-Iduronidase expression in murine and human hematopoietic cells using toxicology and biodistribution good laboratory practice studies","volume":"27","author":"Visigalli","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0105","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1517\/17425247.2015.966682","article-title":"Gene therapy for neurologic manifestations of mucopolysaccharidoses","volume":"12","author":"Wolf","year":"2015","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.ymgmr.2020.100604_bb0110","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ymthe.2004.03.011","article-title":"Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene","volume":"9","author":"Hartung","year":"2004","journal-title":"Mol Therap."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0115","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ana.20150","article-title":"Prevention of neuropathology in the mouse model of Hurler syndrome","volume":"56","author":"Desmaris","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ymgme.2006.08.001","article-title":"Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice","volume":"90","author":"Chung","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0125","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/sj.mt.6300201","article-title":"Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy","volume":"15","author":"Traas","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.nbd.2011.02.015","article-title":"Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of muco- polysaccharidosis type I","volume":"43","author":"Wolf","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0135","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.ymthe.2004.10.006","article-title":"Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector","volume":"11","author":"Kobayashi","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0140","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1227\/NEU.0000000000000157","article-title":"Comparison of endovascular and intraventricular gene therapy with adeno-associated virus-\u03b1-L-iduronidase for Hurler disease","volume":"74","author":"Janson","year":"2014","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ymgmr.2020.100604_bb0145","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1038\/mt.2014.135","article-title":"Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I","volume":"22","author":"Hinderer","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.ymgmr.2020.100604_bb0150","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/mt.2015.99","article-title":"Neonatal systemic AAV induces tolerance to CNS gene therapy in MPS I dogs and nonhuman primates","volume":"23","author":"Hinderer","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0155","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2010.265","article-title":"Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes","volume":"19","author":"Ellinwood","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0160","doi-asserted-by":"crossref","first-page":"14894","DOI":"10.1073\/pnas.1413645111","article-title":"Liver-directed gene therapy corrects cardiovascular lesions in feline mucopolysaccharidosis type I","volume":"111","author":"Hinderer","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.ymgmr.2020.100604_bb0165","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1089\/hum.2017.187","article-title":"Intranasal adeno-associated virus mediated gene delivery and expression of human Iduronidase in the central nervous system: a noninvasive and effective approach for prevention of neurologic disease in mucopolysaccharidosis type I","volume":"28","author":"Belur","year":"2017","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.ymgmr.2020.100604_bb0170","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ymthe.2018.10.018","article-title":"ZFN-mediated in vivo genome editing corrects murine hurler syndrome","volume":"27","author":"Ou","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0175","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.omtm.2018.06.003","article-title":"Toxicology study of intra-cisterna magna adeno-associated virus 9 expressing human alpha-L-Iduronidase in rhesus macaques","volume":"10","author":"Hordeaux","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0180","article-title":"Safe and sustained expression of human Iduronidase after intrathecal Administration of Adeno-Associated Virus Serotype 9 in infant rhesus monkeys","volume":"10","author":"Hordeaux","year":"2019","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.ymgmr.2020.100604_bb0185","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"issue":"7","key":"10.1016\/j.ymgmr.2020.100604_bb0190","first-page":"1187","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","volume":"17","author":"Duque","year":"2009","journal-title":"MolTher."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0195","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/mt.2014.68","article-title":"Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10","volume":"22","author":"Yang","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0200","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1089\/humc.2013.239","article-title":"Comparative efficacy and safety of multiple routes of direct CNS administration of adeno-associated virus gene transfer vector serotype rh.10 expressing the human arylsulfatase A cDNA to nonhuman primates","volume":"25","author":"Rosenberg","year":"2014","journal-title":"Hum. Gene Ther. Dev."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0205","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/mt.2011.72","article-title":"Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates","volume":"19","author":"Gray","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0210","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/mt.2011.98","article-title":"Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system","volume":"19","author":"Zhang","year":"2011","journal-title":"Mol. Ther."},{"issue":"18","key":"10.1016\/j.ymgmr.2020.100604_bb0215","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0220","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/sj.gt.3302087","article-title":"Adeno-associated virus vector-mediated transduction in the cat brain","volume":"10","author":"Vite","year":"2003","journal-title":"Gene Ther."},{"issue":"19","key":"10.1016\/j.ymgmr.2020.100604_bb0225","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.1093\/hmg\/ddv271","article-title":"Neuropeptide Y mitigates neuropathology and motor deficits in mouse models of Machado\u2013Joseph disease","volume":"24","author":"Duarte-Neves","year":"2015","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.ymgmr.2020.100604_bb0230","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1089\/humc.2017.231","article-title":"AAVrh.10-mediated APOE2 central nervous system gene therapy for APOE4-associated Alzheimer\u2019s disease","volume":"29","author":"Rosenberg","year":"2018","journal-title":"Hum Gene Ther Clin Dev."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0235","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jconrel.2016.09.011","article-title":"Pereira de Almeida L. gene therapy for the CNS using AAVs: the impact of systemic delivery by AAV9","volume":"241","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ymgmr.2020.100604_bb0240","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.omtm.2018.07.005","article-title":"Targeting root cause by systemic scAAV9-hIDS gene delivery: functional correction and reversal of severe MPS II in mice","volume":"10","author":"Fu","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"9","key":"10.1016\/j.ymgmr.2020.100604_bb0245","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86696","article-title":"CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)","volume":"1","author":"Motas","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymgmr.2020.100604_bb0250","article-title":"Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy","volume":"1","author":"Haurigot","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.ymgmr.2020.100604_bb0255","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1073\/pnas.252784899","article-title":"Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB","volume":"100","author":"Ohmi","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.ymgmr.2020.100604_bb0260","first-page":"792","article-title":"Near-complete correction of profound Metabolomic impairments corresponding to functional benefit in MPS IIIB mice after IV rAAV9-hNAGLU gene delivery","volume":"25","author":"Fu","year":"2017","journal-title":"MolTher."},{"issue":"2","key":"10.1016\/j.ymgmr.2020.100604_bb0265","first-page":"206","article-title":"De Guilhem, De Lataillade a, Bell P, et al. evaluation of AAV-mediated gene therapy for central nervous system disease in canine Mucopolysaccharidosis VII","volume":"24","author":"Gurda","year":"2016","journal-title":"MolTher."},{"issue":"15","key":"10.1016\/j.ymgmr.2020.100604_bb0270","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1093\/hmg\/ddv168","article-title":"Systemic AAV9 gene transfer in adult GM1 gangliosidosis mice reduces lysosomal storage in CNS and extends lifespan","volume":"24","author":"Weismann","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0275","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/mt.2014.240","article-title":"Long-term correction of Sandhoff disease following intravenous delivery of rAAV9 to mouse neonates","volume":"23","author":"Walia","year":"2015","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.ymgmr.2020.100604_bb0280","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/mt.2010.299","article-title":"Efficacy of a combined intra- cerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder","volume":"19","author":"Spampanato","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0285","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/gt.2014.17","article-title":"Long-term correction of biochemical and neurological abnormalities in MLD mice model by neonatal systemic injection of an AAV serotype 9 vector","volume":"21","author":"Miyake","year":"2014","journal-title":"Gene Ther."},{"issue":"8","key":"10.1016\/j.ymgmr.2020.100604_bb0290","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/mt.2013.95","article-title":"Mouse gender influences brain transduction by intravascularly administered AAV9","volume":"21","author":"Maguire","year":"2013","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.ymgmr.2020.100604_bb0295","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/mt.2011.157","article-title":"Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders","volume":"19","author":"Bevan","year":"2011","journal-title":"Mol Ther."},{"issue":"1","key":"10.1016\/j.ymgmr.2020.100604_bb0300","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.mt.6300331","article-title":"AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method","volume":"16","author":"Klein","year":"2008","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.ymgmr.2020.100604_bb0305","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/gt.2009.157","article-title":"High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency","volume":"17","author":"Ayuso","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0310","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3171\/FOC\/2008\/24\/3-4\/E11","article-title":"Central nervous system therapy for lysosomal storage disorders","volume":"24","author":"Enns","year":"2008","journal-title":"Neurosurg. Focus."},{"issue":"2","key":"10.1016\/j.ymgmr.2020.100604_bb0315","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ymgme.2013.09.008","article-title":"High-dose enzyme replacement therapy in murine hurler syndrome","volume":"111","author":"Ou","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0320","doi-asserted-by":"crossref","first-page":"14777","DOI":"10.1073\/pnas.0506892102","article-title":"Over- coming the blood\u2013brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII","volume":"102","author":"Vogler","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0325","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1093\/hmg\/ddn237","article-title":"Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice","volume":"17","author":"Blanz","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0330","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/mt.2008.305","article-title":"Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy","volume":"17","author":"Matzner","year":"2009","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.ymgmr.2020.100604_bb0335","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.ymthe.2018.03.002","article-title":"Dose-dependent prevention of metabolic and neurologic disease in murine MPS II by ZFN-mediated in vivo genome editing","volume":"26","author":"Laoharawee","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0340","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.162.3853.570","article-title":"Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts","volume":"162","author":"Fratantoni","year":"1968","journal-title":"Science"},{"key":"10.1016\/j.ymgmr.2020.100604_bb0345","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1096\/fasebj.1.6.3315809","article-title":"Trafficking of lysosomal enzymes","volume":"1","author":"Kornfeld","year":"1987","journal-title":"FASEB J."},{"key":"10.1016\/j.ymgmr.2020.100604_bb0350","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fnana.2014.00042","article-title":"Biodistribution of adeno-associated virus serotype 9 (AAV9) after intrathecal and intravenous delivery in mouse","volume":"8","author":"Schuster","year":"2014","journal-title":"Front. Neuroanat."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426920300501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426920300501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:51:05Z","timestamp":1762001465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426920300501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":70,"alternative-id":["S2214426920300501"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2020.100604","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous delivery for treatment of mucopolysaccharidosis type I: A comparison of AAV serotypes 9 and rh10","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2020.100604","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100604"}}